Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -44.68% is 14% above its 5-year average of -52.03%, around the middle of its 5-year range (-88.36%–-22.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.01% below its 12-month average of -40.25%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -44.68%.
RETURN ON EQUITY (ROE)
-44.68%
RETURN ON EQUITY (ROE) AVG TTM
-40.25%
RETURN ON EQUITY (ROE) AVG 3Y
-60.28%
RETURN ON EQUITY (ROE) AVG 5Y
-52.03%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-11.01%
CURRENT VS 3Y AVG
+25.88%
CURRENT VS 5Y AVG
+14.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.55%
median of 491 covered companies
CURRENT VS SECTOR MEDIAN
-15.90%
vs the sector median at left
Adaptive Biotechnologies Corporation
Market Cap
$4.58B
Return on Equity (ROE)
-44.68%
TTM Avg
-40.25%
3Y Avg
-60.28%
5Y Avg
-52.03%
Market Cap
$4.69B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
Market Cap
$4.73B
Return on Equity (ROE)
-38.51%
TTM Avg
-50.16%
3Y Avg
-65.11%
5Y Avg
-61.13%
Market Cap
$4.80B
Return on Equity (ROE)
-2.55%
TTM Avg
-28.50%
3Y Avg
-30.36%
5Y Avg
-30.19%
Market Cap
$4.86B
Return on Equity (ROE)
N/A
TTM Avg
-23.20%
3Y Avg
-51.91%
5Y Avg
-56.25%
Market Cap
$4.44B
Return on Equity (ROE)
N/A
TTM Avg
-107.43%
3Y Avg
-58.28%
5Y Avg
-52.10%
Market Cap
$4.43B
Return on Equity (ROE)
-42.32%
TTM Avg
-13.82%
3Y Avg
-5.11%
5Y Avg
-5.11%
Market Cap
$4.99B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.99B
Return on Equity (ROE)
-79.37%
TTM Avg
-38.23%
3Y Avg
-43.73%
5Y Avg
-49.41%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Adaptive Biotechnologies Corporation (ADPT) | $4.58B | -44.68% | -40.25% | -60.28% | -52.03% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 3.43% | -1.67% | -7.64% | -9.04% |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.73B | -38.51% | -50.16% | -65.11% | -61.13% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.80B | -2.55% | -28.50% | -30.36% | -30.19% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.86B | N/A | -23.20% | -51.91% | -56.25% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.44B | N/A | -107.43% | -58.28% | -52.10% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.43B | -42.32% | -13.82% | -5.11% | -5.11% |
| BillionToOne, Inc. (BLLN)vs › | $4.99B | 6.24% | -11.62% | -98.18% | -98.18% |
| Erasca, Inc. (ERAS)vs › | $4.99B | -79.37% | -38.23% | -43.73% | -49.41% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.33B | -44.02% | -30.64% | -28.05% | -12.80% |
ROE
-44.7%
ROA
-10.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -44.68% |
| 2026-03-31 | -22.96% |
| 2025-12-31 | -27.19% |
| 2025-09-30 | -38.94% |
| 2025-06-30 | -67.46% |
| 2025-03-31 | -74.49% |
| 2024-12-31 | -78.68% |
| 2024-09-30 | -87.25% |
| 2024-06-30 | -88.36% |
| 2024-03-31 | -78.23% |
| 2023-12-31 | -73.04% |
| 2023-09-30 | -54.17% |
| 2023-06-30 | -48.21% |
| 2023-03-31 | -46.02% |
| 2022-12-31 | -43.14% |
| 2022-09-30 | -45.40% |
| 2022-06-30 | -44.78% |
| 2022-03-31 | -41.46% |
| 2021-12-31 | -34.30% |
| 2021-09-30 | -29.23% |
| 2021-06-30 | -24.70% |
| 2021-03-31 | -21.43% |
| 2020-12-31 | -19.67% |
| 2020-09-30 | -15.78% |
| 2020-06-30 | -18.78% |
| 2020-03-31 | -14.80% |
| 2019-12-31 | -12.01% |
| 2019-09-30 | -10.46% |
| 2019-03-31 | -18.20% |
